Bausch + Lomb Corp (BLCO)

$15.91

up-down-arrow $-0.09 (-0.56%)

As on 07-May-2026 16:10EDT

Market cap

info icon

$5,705 Mln

Revenue (TTM)

info icon

$5,203 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.9

Div. Yield

info icon

0 %

Value Research Rating

--

Quality Score fund-quick-summary-circle

Quality Score/10

Growth Score fund-quick-summary-circle

Growth Score/10

Valuation Score fund-quick-summary-circle

Valuation Score/10

Momentum Score fund-quick-summary-circle

Momentum Score/10

Bausch + Lomb Corp (BLCO) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 15.89 High: 16.15

52 Week Range

Low: 10.85 High: 18.92

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.1 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    16.6

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-0.6

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    356,536,358

6 Years Aggregate

CFO

$3,285.00 Mln

EBITDA

$4,526.00 Mln

Net Profit

$928.00 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Bausch + Lomb Corp (BLCO)
-6.9 -2.6 -3.0 46.0 -3.1 -- --
BSE Sensex*
-8.7 3.6 -7.5 -4.2 8.2 9.5 11.9
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 07-May-2026  |  *As on 08-May-2026  |  #As on 26-Oct-2023
Company
2025
2023
Bausch + Lomb Corp (BLCO)
-5.4 10.0
S&P Small-Cap 600
4.0 13.9
BSE Sensex
9.1 18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Bausch + Lomb Corp (BLCO)
15.9 5,704.6 5,203.0 -219.0 4.6 -3.5 -- 0.9
7.2 262.0 16.4 42.3 -260.2 55.9 -- 3.7
3.7 162.3 285.3 -10.7 -0.9 -9.2 -- 1.6
9.2 326.4 270.3 14.9 8.6 10.9 23 2.6

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Bausch + Lomb Corp (BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision...  Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4  Read more

  • Executive VP & CFO

    Mr. Osama A. Eldessouky

  • CEO & Chairman

    Mr. Brenton L. Saunders J.D.

  • Headquarters

    Vaughan, ON

  • Website

    https://www.bausch.com

Edit peer-selector-edit
loading...
loading...

FAQs for Bausch + Lomb Corp (BLCO)

The share price of Bausch + Lomb Corp (BLCO) is $15.91 (NYSE) as of 07-May-2026 16:10 EDT. Bausch + Lomb Corp (BLCO) has given a return of -3.13% in the last 3 years.

Since, TTM earnings of Bausch + Lomb Corp (BLCO) is negative, P/E ratio is not available.
The P/B ratio of Bausch + Lomb Corp (BLCO) is 0.91 times as on 07-May-2026, a 66 discount to its peers’ median range of 2.66 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
-16.79
0.94
2024
-20.04
0.98
2023
-23.02
0.87
2022
904.75
0.77
2021
--
--

The 52-week high and low of Bausch + Lomb Corp (BLCO) are Rs 18.92 and Rs 10.85 as of 08-May-2026.

Bausch + Lomb Corp (BLCO) has a market capitalisation of $ 5,705 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Bausch + Lomb Corp (BLCO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.